While the India-U.K. CETA eases trade barriers, critical gaps in investment protection, patent laws, and carbon taxes remain unresolved for future negotiations.

Key Takeaways

  • CETA has cut tariffs on 99% of Indian exports but lacks a dedicated investment treaty.
  • India successfully protected Section 3(d) of its Patent Act to prevent drug 'evergreening'.
  • The UK's upcoming Carbon Border Tax (CBAM) threatens to offset tariff benefits for Indian industry.

The implementation of the India-U.K. Comprehensive Economic and Trade Agreement (CETA) on July 15, 2026, marks a significant milestone in bilateral relations. By slashing tariffs on 99% of Indian exports and easing mobility rules for professionals, the deal aims to boost economic exchange. However, as noted by Commerce Minister Piyush Goyal, the agreement is incomplete, leaving several contentious issues for future deliberation.

The Investment Gap

A glaring omission in the CETA is the lack of a dedicated investment protection framework, unlike India's agreements with the European Free Trade Association (EFTA). The primary roadblock remains the dispute resolution mechanism. Following India's 2017 decision to overhaul its Bilateral Investment Treaties (BITs), a stalemate exists between India's insistence on domestic legal recourse and the UK's preference for international arbitration.

Pharmaceuticals and Patent Wars

Despite lower tariffs, UK pharmaceutical giants face a steep climb in the Indian market. India has steadfastly defended Section 3(d) of the Patents Act, 1970, which prevents companies from obtaining new patents through minor modifications to existing drugs—a practice known as 'evergreening'. This protection ensures that Indian generic manufacturers can continue to provide affordable medicine, a sector where the UK currently holds a minimal 0.5% market share in India.

Why This Matters

BozokMedia analysis shows that the success of this trade pact will not be measured by immediate tariff reductions alone, but by how effectively both nations navigate the upcoming regulatory hurdles. The tension between protecting domestic industries and embracing global liberalisation is palpable.

The absence of a robust investment treaty leaves a vacuum of certainty that could deter long-term capital inflows.

Furthermore, the UK’s Carbon Border Adjustment Mechanism (CBAM), set for 2027, looms large. This tax on carbon-intensive imports like steel and aluminum could effectively neutralize the trade advantages gained through CETA, creating a new layer of complexity for Indian exporters.

Did You Know?: While the UK exports £26 billion in medicines globally, only a tiny fraction—about 0.5%—reaches the Indian market.

Frequently Asked Questions

1. What is the main benefit of the CETA for India?
It significantly reduces import duties on nearly all Indian exports to the UK.

2. How does Section 3(d) affect trade?
It prevents pharmaceutical companies from extending patent monopolies through minor drug changes, favoring generic competition.